We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-10%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.64B
AUM Growth
-$98.2M
Cap. Flow
+$187M
Cap. Flow %
11.36%
Top 10 Hldgs %
46.02%
Holding
79
New
7
Increased
13
Reduced
45
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.9M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.3M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$18.4M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$18.2M
5
QURE icon
uniQure
QURE
+$17.3M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$20.8M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15.6M
3
ALLK
Allakos
ALLK
+$13.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.3M
5
ANAB icon
AnaptysBio
ANAB
+$5.18M

Sector Composition

Rank Sector Weight
1 Healthcare 82.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
51
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$7.84M 0.48%
1,213,274
-58,411
-5% -$488K
RARX
52
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$6.99M 0.43%
295,600
-54,400
-16% -$1.61M
AUTL
53
Autolus Therapeutics
AUTL
$506M
$5.96M 0.36%
479,988
-220,012
-31% -$2.91M
GNFT
54
DELISTED
Genfit
GNFT
$5.22M 0.32%
300,000
-19,700
-6% -$344K
BCEL
55
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.97M 0.3%
406,142
-38,800
-9% -$590K
NERV icon
56
Minerva Neurosciences
NERV
$203M
$4.71M 0.29%
75,988
– –
QTTB icon
57
Q32 Bio
QTTB
$490M
$4.44M 0.27%
13,617
-3,050
-18% -$1.04M
ATRA icon
58
Atara Biotherapeutics
ATRA
$76.9M
$4.24M 0.26%
12,000
-4,000
-25% -$1.49M
DTIL icon
59
Precision BioSciences
DTIL
$193M
$3.92M 0.24%
15,584
– –
RUBY
60
DELISTED
Rubius Therapeutics, Inc
RUBY
$3.86M 0.24%
491,700
-108,300
-18% -$1.26M
NBIX icon
61
Neurocrine Biosciences
NBIX
$16.4B
$3.54M 0.22%
39,300
-10,700
-21% -$1,000K
PHAS
62
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.4M 0.21%
816,448
-89,781
-10% -$716K
KZR
63
DELISTED
Kezar Life Sciences
KZR
$3.04M 0.19%
92,787
-4,042
-4% -$195K
IGMS
64
DELISTED
IGM Biosciences
IGMS
$2.78M 0.17%
+156,400
New +$3.16M
ITRM
65
DELISTED
Iterum Therapeutics
ITRM
$2.34M 0.14%
26,426
– –
ADVM
66
CALL
DELISTED
Adverum Biotechnologies
ADVM
$1.64M 0.1%
+30,000
New +$3.38M
BOLD
67
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.41M 0.09%
50,000
-25,000
-33% -$853K
SRRK icon
68
Scholar Rock
SRRK
$5.74B
$1.06M 0.06%
118,950
-31,050
-21% -$371K
GTHX
69
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.02M 0.06%
+1,000
New +$31.5K
XLRN
70
DELISTED
Acceleron Pharma
XLRN
$988K 0.06%
25,000
-15,000
-38% -$651K
IFRX icon
71
InflaRx
IFRX
$261M
$741K 0.05%
300,000
-1,200,000
-80% -$3.49M
ABEO icon
72
Abeona Therapeutics
ABEO
$388M
$452K 0.03%
8,000
-6,000
-43% -$449K
ACRS icon
73
Aclaris Therapeutics
ACRS
$888M
$270K 0.02%
250,000
– –
OTLKW
74
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$50K ﹤0.01%
416,666
– –
OTLK icon
75
Outlook Therapeutics
OTLK
$193M
$23K ﹤0.01%
788
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Cormorant Asset Management held 79 positions worth $1.64B, down 5.6% from $1.74B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $187M of net new capital in Q3 2019, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $13.6M trimmed.

  • Cormorant Asset Management's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.
  • Cormorant Asset Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $46.9M increase.
  • Cormorant Asset Management's biggest Q3 2019 reduction was Allakos, cutting an estimated $13.6M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $20.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.64B portfolio in Q3 2019.
  • Cormorant Asset Management opened 7 new positions and closed 4 in Q3 2019.
  • Cormorant Asset Management's portfolio value fell 5.6% quarter-over-quarter to $1.64B.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.